The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson’s Consortium formally submitted documentation to the European Medicines Agency (EMA) supporting the use of Dopamine Transporter (DAT) neuroimaging in early PD. Regulatory documents included a comprehensive literature review, a proposed analysis plan of both observational and clinical trial data, and an assessment of biomarker reproducibility and reliability. The research plan included longitudinal analysis of the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) and the Parkinson’s Progression Markers Initiative (PPMI) study to estimate the degree of enrichment achieved and impact on future trials in subjects with early motor PD. The presence of reduced striatal DAT binding based on visual reads of single photon emission tomography (SPECT) scans in early motor PD subjects was an independent predictor of faster decline in UPDRS Parts II and III as compared to subjects with scans without evidence of dopaminergic deficit (SWEDD) over 24 months. The EMA issued in 2018 a full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor symptoms. Exclusion of SWEDD subjects in future clinical trials targeting early motor PD subjects aims to enrich clinical trial populations with idiopathic PD patients, improve statistical power, and exclude subjects who are unlikely to progress clinically from being exposed to novel test therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig.2 The proportion of subjects with absence of DAT deficit in clinical trials increases with earlier stages of PD. A number of PD clinical studies have identified subjects defined as SWEDD by employing DAT imaging at baseline and follow up. The proportion of subjects defined as SWEDD decreases with the time since diagnosis for those in specific PD clinical studies targeting early stages of the disease. The proportion of SWEDD subjects is lower in studies enrolling subjects with longer duration of disease. As sponsors enroll PD subjects earlier in the disease (i.e., sooner after diagnosis), the value (benefit) of DAT imaging for enrichment increases. References for PD clinical studies: [38, 39, 41, 59– 61]. ELLDOPA: Levodopa; PRECEPT: Mixed Lineage Kinase Inhibitor CEP 1347; REAL-PD: Ropinirole; CALM-PD: Pramipexole; GPI1485: Immunophilin; PPMI: Parkinson’s Progression Markers Initiative.](https://figures.cochat.ai/paper-figures/c67f8a2c856f42f3908b4d598270846f/the-qualification-of-an-enrichment-biomarker-for-clinical-trials-targeting-early-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005 · cited 1×
“Novel therapeutic development efforts are underway targeting -synuclein [11] and the two most common genetic causes of PD, glucocerebrosidase (GBA) deficiency [12], and mutated forms of leucine rich repeat kinase 2 (LRRK2) [4, 13].”
BackgroundThe Emerging Evidence of the Parkinson Pandemic
Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-181474 · Cited by 1,977 · cited 1×
“Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 2% to 3% of people over 65 years of age [1] and has been recently reported to be the most rapidly growing neurological disease [2, 3].”
BackgroundThe Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Self-citationDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A., Simcox, E., & Turnbull, D. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 947 · cited 1×
“Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 2% to 3% of people over 65 years of age [1] and has been recently reported to be the most rapidly growing neurological disease [2, 3].”
BackgroundAccuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis
Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., & Logroscino, G. (2016) · Neurology · doi:10.1212/wnl.0000000000002350 · Cited by 870 · cited 1×
“It can, however, be challenging to diagnose PD, especially in early stage disease when other neurological disorders can present with similar signs and symptoms [16, 17].”
BackgroundSlower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Benamer, H. T. S., Patterson, J., Grosset, D. G., Booij, J., de Bruin, K., van Royen, E., Speelman, J. D., Horstink, M. H. I. M., Sips, H. J. W. A., Dierckx, R. A., et al. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<503::aid-mds1013>3.0.co;2-v · Cited by 707 · cited 1×
“Reductions of DAT radiotracer binding (DAT deficit) correlate with the disease duration from early stages of the disease [34], matching pathological findings from DAT immunohistochemistry [35].”
BackgroundSelf-citationBiochemical aspects of Parkinson's disease
Hornykiewicz, O. (1998) · Neurology · doi:10.1212/wnl.51.2_suppl_2.s2 · Cited by 564 · cited 1×
“In fact, we have learned that motor symptoms are only apparent after profound loss of dopaminergic neurons in PD [15].”
BackgroundLow clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study
Adler, C. H., Beach, T. G., Hentz, J. G., Shill, H. A., Caviness, J. N., Driver-Dunckley, E., Sabbagh, M. N., Sue, L. I., Jacobson, S. A., Belden, C. M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000641 · Cited by 503 · cited 2×
“It can, however, be challenging to diagnose PD, especially in early stage disease when other neurological disorders can present with similar signs and symptoms [16, 17].”
BackgroundLang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Darcourt, J., Booij, J., Tatsch, K., Varrone, A., Vander Borght, T., Kapucu, Ö. L., Någren, K., Nobili, F., Walker, Z., & Van Laere, K. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1267-x · Cited by 346
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
The Parkinson Study Group PRECEPT Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000277648.63931.c0 · Cited by 292
The burden of Parkinson's disease: a worldwide perspective
Rocca, W. A. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30355-7 · Cited by 270 · cited 1×
“Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 2% to 3% of people over 65 years of age [1] and has been recently reported to be the most rapidly growing neurological disease [2, 3].”
BackgroundSNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0
Djang, D. S. W., Janssen, M. J. R., Bohnen, N., Booij, J., Henderson, T. A., Herholz, K., Minoshima, S., Rowe, C. C., Sabri, O., Seibyl, J., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.100784 · Cited by 247 · cited 3×
“The dopamine transporter (DAT), a transporter protein that is located on the presynaptic terminal of dopaminergic neurons, can be imaged with specific molecular radiotracers [33].”
BackgroundMethodSelf-citationParkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial
Fahn, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.529 · Cited by 245
A randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson disease
The NINDS NET-PD Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000250355.28474.8e · Cited by 219
Amur, S., LaVange, L., Zineh, I., Buckman‐Garner, S., & Woodcock, J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.136 · Cited by 211
Autosomal dominant Parkinson's disease caused by SNCA duplications
Konno, T., Ross, O. A., Puschmann, A., Dickson, D. W., & Wszolek, Z. K. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.007 · Cited by 210 · cited 1×
“Rare point mutations and the presence of extra copies of the synuclein gene result in autosomal dominant PD [9, 10].”
BackgroundMIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE
Wang, L. H., & Johnson, E. M. (2008) · Neurology · doi:10.1212/01.wnl.0000324506.93877.5e · Cited by 204
Bajaj, N., Hauser, R. A., & Grachev, I. D. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304436 · Cited by 204 · cited 1×
“At present, this DAT imaging agent is approved for clinical use to assist in the evaluation of patients with suspected parkinsonian syndromes to distingusih PD from essential tremor [46].”
BackgroundJennings, D., Siderowf, A., Stern, M., Seibyl, J., Eberly, S., Oakes, D., Marek, K., & for the PARS Investigators (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0985 · Cited by 200
Self-citationEspay, A. J., Schwarzschild, M. A., Tanner, C. M., Fernandez, H. H., Simon, D. K., Leverenz, J. B., Merola, A., Chen‐Plotkin, A., Brundin, P., Kauffman, M. A., et al. (2017) · Movement Disorders · doi:10.1002/mds.26913 · Cited by 178
Imaging biomarkers in Parkinson's disease
Brooks, D. J., & Pavese, N. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.009 · Cited by 170 · cited 1×
“However, neuroimaging biomarkers, particularly ones probing the dopaminergic system in the brain, have been employed in PD clinical trials for many years [31, 32].”
BackgroundTargeted Therapies for Parkinson's Disease: From Genetics to the Clinic
Sardi, S. P., Cedarbaum, J. M., & Brundin, P. (2018) · Movement Disorders · doi:10.1002/mds.27414 · Cited by 170
Self-citationLongitudinal follow-up of SWEDD subjects in the PRECEPT Study
Marek, K., Seibyl, J., Eberly, S., Oakes, D., Shoulson, I., Lang, A. E., Hyson, C., Jennings, D., & For The Parkinson Study Group PRECEPT Investigators (2014) · Neurology · doi:10.1212/wnl.0000000000000424 · Cited by 168 · cited 13×
“The CPP consortium recognizes Dr. Ira Shoulson for his leadership as principal investigator of the PRECEPT study in addition to the Parkinson’s Study Group.”
MethodInfluentialSelf-citationErro, R., Schneider, S. A., Stamelou, M., Quinn, N. P., & Bhatia, K. P. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310256 · Cited by 148
Glucocerebrosidase is shaking up the synucleinopathies
Siebert, M., Sidransky, E., & Westbroek, W. (2014) · Brain · doi:10.1093/brain/awu002 · Cited by 147 · cited 1×
“Novel therapeutic development efforts are underway targeting -synuclein [11] and the two most common genetic causes of PD, glucocerebrosidase (GBA) deficiency [12], and mutated forms of leucine rich repeat kinase 2 (LRRK2) [4, 13].”
BackgroundFinding useful biomarkers for Parkinson’s disease
Chen-Plotkin, A. S., Albin, R., Alcalay, R., Babcock, D., Bajaj, V., Bowman, D., Buko, A., Cedarbaum, J., Chelsky, D., Cookson, M. R., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6003 · Cited by 146
Self-citationImportance of low diagnostic Accuracy for early Parkinson's disease
Beach, T. G., & Adler, C. H. (2018) · Movement Disorders · doi:10.1002/mds.27485 · Cited by 135
Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease
Ravina, B., Marek, K., Eberly, S., Oakes, D., Kurlan, R., Ascherio, A., Beal, F., Beck, J., Flagg, E., Galpern, W. R., et al. (2012) · Movement Disorders · doi:10.1002/mds.25157 · Cited by 133
Self-citationAbi‐Dargham, A., Gandelman, M. S., DeErausquin, G. A., Zea‐Ponce, Y., Zoghbi, S. S., Baldwin, R. M., Laruelle, M., Charney, D. S., Hoffer, P. B., Neumeyer, J. L., et al. (1996) · PubMed · Cited by 125
(2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200001000-00007 · Cited by 117
Molecular imaging of dopamine transporters
Brooks, D. J. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2015.12.009 · Cited by 114 · cited 2×
“However, neuroimaging biomarkers, particularly ones probing the dopaminergic system in the brain, have been employed in PD clinical trials for many years [31, 32].”
BackgroundMethodHill, D. L. G., Schwarz, A. J., Isaac, M., Pani, L., Vamvakas, S., Hemmings, R., Carrillo, M. C., Yu, P., Sun, J., Beckett, L., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.07.003 · Cited by 96 · cited 1×
“An example is the use of low baseline hippocampal volume as an enrichment biomarker to identify predementia subjects more likely to progress in a clinical trial for early Alzheimer’s disease [26].”
MethodSelf-citationα-synuclein Imaging: A Critical Need for Parkinson's Disease Research
Eberling, J. L., Dave, K. D., & Frasier, M. A. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130247 · Cited by 80 · cited 3×
“There is not yet a reliable biofluid or imaging biomarker of -synuclein to enrich PD clinical trial populations [19, 20, 30, 57].”
BackgroundWhat evidence do we need for biomarker qualification?
Leptak, C., Menetski, J. P., Wagner, J. A., Aubrecht, J., Brady, L., Brumfield, M., Chin, W. W., Hoffmann, S., Kelloff, G., Lavezzari, G., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4599 · Cited by 78 · cited 1×
“Regulators also offer biomarker qualification, a public and formal review process to accelerate the adoption of drug development tools across targets and sponsors [23, 27, 28].”
BackgroundOlgiati, S., Thomas, A., Quadri, M., Breedveld, G. J., Graafland, J., Eussen, H. J., Douben, H., de Klein, A., ONOFRJ, M. C., & Bonifati, V. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.06.005 · Cited by 69 · cited 1×
“Rare point mutations and the presence of extra copies of the synuclein gene result in autosomal dominant PD [9, 10].”
BackgroundMerchant, K., Cedarbaum, J. M., Brundin, P., Dave, K. D., Eberling, J. L., Espay, A. J., Hutten, S. J., Javidnia, M., Luthman, J., Maetzler, W., et al. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181471 · Cited by 63 · cited 1×
“There is not yet a reliable biofluid or imaging biomarker of -synuclein to enrich PD clinical trial populations [19, 20, 30, 57].”
BackgroundSelf-citationMolecular Imaging Insights into Neurodegeneration: Focus on α-Synuclein Radiotracers
Shah, M., Seibyl, J. P., Cartier, A. E., Bhatt, R., & Catafau, A. M. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136515 · Cited by 60
Self-citationTherapeutic approaches in Parkinson's disease and related disorders
Valera, E., & Masliah, E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13529 · Cited by 52 · cited 1×
“Cellular processes considered to be valid targets for drug development include the molecular processes leading to -synuclein accumulation (synthesis, aggregation and clearance), as well as mitochondrial dysfunction and neuroinflammation [14].”
BackgroundInsomnia and somnolence in idiopathic RBD: a prospective cohort study
Postuma, R. B., Gagnon, J.-F., Pelletier, A., & Montplaisir, J. Y. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0011-7 · Cited by 49 · cited 2×
“contemporary Alzheimer’s disease trials, an amyloid PET scan has been used to enrich the clinical trial population by excluding subjects without fibrillar amyloid deposits in their brain [55].”
MethodConrado, D. J., Nicholas, T., Tsai, K., Macha, S., Sinha, V., Stone, J., Corrigan, B., Bani, M., Muglia, P., Watson, I. A., et al. (2018) · Clinical and Translational Science · doi:10.1111/cts.12492 · Cited by 49
Self-citationZeroing in on neurodegenerative α-synuclein
Kingwell, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.95 · Cited by 47
Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease 1
Stephenson, D. T., Hu, M. T., Romero, K., Breen, K. C., Burn, D. J., Ben‐Shlomo, Y., Bhattaram, A., Isaac, M., Venuto, C. S., Kubota, K., et al. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150570 · Cited by 32 · cited 1×
“The Critical Path for Parkinson’s (CPP) is a global public-private partnership to accelerate drug development in PD [47].”
BackgroundSelf-citationElephants, Parkinson's Disease, and Proof‐of‐Concept Clinical Trials
Cedarbaum, J. M. (2018) · Movement Disorders · doi:10.1002/mds.27398 · Cited by 31
Self-citationSingle-photon emission tomography and dopamine transporter imaging in Parkinson's disease.
MAREK, K. L., Jennings, D. L., & Seibyl, J. P. (2003) · PubMed · Cited by 20
Self-citationRomero, K., Conrado, D. J., Burton, J. K., Nicholas, T., Sinha, V. P., Macha, S., Ahamadi, M., Cedarbaum, J. M., Seibyl, J. P., MAREK, K. L., et al. (2019) · Clinical and Translational Science · doi:10.1111/cts.12619 · Cited by 19
Self-citationThe European Medicines Agency Experience with Biomarker Qualification
Manolis, E., Koch, A., Deforce, D. L. D., & Vamvakas, S. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1872-0_15 · Cited by 17 · cited 1×
“Regulators also offer biomarker qualification, a public and formal review process to accelerate the adoption of drug development tools across targets and sponsors [23, 27, 28].”
BackgroundSelf-citationThe European Medicines Agency's strategies to meet the challenges of Alzheimer disease
Haas, M., Mantua, V., Haberkamp, M., Pani, L., Isaac, M., Butlen‐Ducuing, F., Vamvakas, S., & Broich, K. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4585 · Cited by 14
Self-citationKieburtz, K. D., Katz, R. G., & Olanow, C. W. (2017) · Movement Disorders · doi:10.1002/mds.27220 · Cited by 13 · cited 2×
“The selection of biomarkers for use in clinical trials conventionally merits a confidential discussion between the regulator and the study’s sponsor [5].”
BackgroundKoros, C., Simitsi, A., Prentakis, A. G., Beratis, I., Papadimitriou, D. A., Kontaxopoulou, D., Fragkiadaki, S., Papagiannakis, N., Seibyl, J. P., MAREK, K. L., et al. (2018) · Movement Disorders · doi:10.1002/mds.27451 · Cited by 13 · cited 1×
“Recent studies demonstrate DAT deficit may be augmented in synuclein mutation PD subjects [36].”
BackgroundSelf-citationThe Role of the Core Imaging Laboratory in Multicenter Trials
Seibyl, J. P., MAREK, K. L., & Zubal, I. G. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2010.03.002 · Cited by 10
Self-citationCNS biomarkers: Potential from a regulatory perspective
Isaac, M., & Wied, C. G. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.03.013 · Cited by 4
Challenges and unfulfilled promises in Parkinson's disease
Stoessl, A. J. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30334-4 · Cited by 4
Research works printed but not linked: 2
- Marek K, 2003, Adv Neurol, 91, 183
- Abi-Dargham A, 1996, J Nucl Med, 37, 1129
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Prange, S., Klinger, H., Laurencin, C., Danaila, T., & Thobois, S. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00942-1 · Cited by 167
“These developments will prove instrumental for the recognition of imaging biomarkers specific to PD depression, which may in turn serve as enrichment biomarkers in clinical trials [313].”
BackgroundThe Parkinson Study Group SURE-PD3 Investigators, Bluett, B., Togasaki, D. M., Mihaila, D., Evatt, M., Rezak, M., Jain, S., Schwarzschild, M. A., Ascherio, A., Casaceli, C., et al. (2021) · JAMA · doi:10.1001/jama.2021.10207 · Cited by 165
Self-citationBiomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 87
“It can limit inclusion of people who are symptomatic without evidence of dopamine degeneration (SWEDD), a group that comprises approximately 15% of cases when using clinical criteria alone 81,82 .”
Stephenson, D., Alexander, R., Aggarwal, V., Badawy, R., Bain, L., Bhatnagar, R., Bloem, B. R., Boroojerdi, B., Burton, J., Cedarbaum, J. M., et al. (2020) · Digital Biomarkers · doi:10.1159/000512500 · Cited by 63
Self-citation
Metadata
- Authors
- Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., Nicholas, T., Matthews, D., Xie, Z., Imam, S., Maguire, P., Russell, D., Gordon, M. F., Stebbins, G. T., Somer, E., Gallagher, J., Roach, A., Basseches, P., Grosset, D., Marek, K., & on behalf of the Critical Path for Parkinson’s Consortium
- Affiliations
- Critical Path Institute (US)
- University College London, UK
- Biogen (United States) (US)
- European Medicines Agency (NL)
- Parkinson's UK (GB)
- Institute for Neurodegenerative Disorders (US)
- Denali Therapeutics (United States) (US)
- Pfizer (United States) (US)
- Archer Daniels Midland (United States) (US)
- National Center for Toxicological Research (US)
- UCB, Brussels, Belgium
- CPP Scientific Advisor, PA, USA
- Rush University (US)
- GE Healthcare, London, UK
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Glasgow (GB)
- Corresponding author
- Stephenson, Diane
- ORCID
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2019-07-08
- Volume
- 9
- Issue
- 3
- Pages
- 553-563
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC6700608
- OpenAlex
- W2958884967
- Cited by
- 46
- References
- 57
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 11 · 2019: 1
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Parkinson's Disease Foundation
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Davis Phinney Foundation
- Strong
- Parkinson's UK
- University of Oxford
- Newcastle University
- University of Glasgow
- Radboud Universiteit
- H. Lundbeck A/S
- U.S. Food and Drug Administration (U18FD005320)
- Merck Sharp and Dohme
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, dopamine transporter SPECT, patient selection, European Medicines Agency, Parkinson's Progression Markers Initiative, dopaminergic deficit, trial enrichment, statistical power
- MeSH terms
- Clinical Studies as Topic, Clinical Trials as Topic, Corpus Striatum, Humans, Parkinson Disease, Societies, Medical, Biomarkers, Tomography, Emission-Computed, Single-Photon, Dopamine Plasma Membrane Transport Proteins, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.